PT2579874T - Composição fluidificável injetável que compreende buprenorfina - Google Patents

Composição fluidificável injetável que compreende buprenorfina

Info

Publication number
PT2579874T
PT2579874T PT117280370T PT11728037T PT2579874T PT 2579874 T PT2579874 T PT 2579874T PT 117280370 T PT117280370 T PT 117280370T PT 11728037 T PT11728037 T PT 11728037T PT 2579874 T PT2579874 T PT 2579874T
Authority
PT
Portugal
Prior art keywords
buprenorphine
flowable composition
injectable flowable
injectable
composition
Prior art date
Application number
PT117280370T
Other languages
English (en)
Portuguese (pt)
Inventor
l norton Richard
Zhou Mingxing
Watkins Andrew
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2579874(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of PT2579874T publication Critical patent/PT2579874T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT117280370T 2010-06-08 2011-06-06 Composição fluidificável injetável que compreende buprenorfina PT2579874T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine

Publications (1)

Publication Number Publication Date
PT2579874T true PT2579874T (pt) 2018-01-29

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117280370T PT2579874T (pt) 2010-06-08 2011-06-06 Composição fluidificável injetável que compreende buprenorfina

Country Status (32)

Country Link
US (1) US8921387B2 (enExample)
EP (3) EP3360538B1 (enExample)
JP (2) JP5986072B2 (enExample)
KR (1) KR101865689B1 (enExample)
CN (1) CN103079544B (enExample)
AU (1) AU2011263478B2 (enExample)
BR (1) BR112012031290A2 (enExample)
CA (1) CA2801676C (enExample)
CL (1) CL2012003462A1 (enExample)
CO (1) CO6670529A2 (enExample)
CY (1) CY1120761T1 (enExample)
DK (2) DK3360538T3 (enExample)
ES (2) ES2939612T3 (enExample)
FI (1) FI3360538T3 (enExample)
GB (2) GB2513267B (enExample)
HR (1) HRP20180118T1 (enExample)
HU (1) HUE038275T2 (enExample)
IL (2) IL223488A (enExample)
LT (1) LT2579874T (enExample)
MX (1) MX339209B (enExample)
MY (1) MY171625A (enExample)
NO (1) NO2579874T3 (enExample)
NZ (1) NZ604026A (enExample)
PL (1) PL2579874T3 (enExample)
PT (1) PT2579874T (enExample)
RS (1) RS56820B1 (enExample)
RU (1) RU2607498C2 (enExample)
SG (1) SG186200A1 (enExample)
SI (1) SI2579874T1 (enExample)
SM (1) SMT201800038T1 (enExample)
WO (1) WO2011154724A2 (enExample)
ZA (1) ZA201209233B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
IN2014DN09238A (enExample) 2012-04-17 2015-07-10 Purdue Pharma Lp
MX387722B (es) * 2012-07-26 2025-03-18 Camurus Ab Formulaciones de opioides.
AU2013294915C1 (en) * 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
MX352907B (es) * 2013-03-15 2017-12-13 Heron Therapeutics Inc Composiciones de un poliortoéster y un solvente aprótico.
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11083730B2 (en) 2014-04-21 2021-08-10 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
BR112016024665B1 (pt) 2014-04-21 2023-04-11 Heron Therapeutics, Inc Composição, composição semissólida e seu uso
EP3134070B1 (en) * 2014-04-21 2020-09-23 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
PT3137081T (pt) 2014-04-28 2018-02-08 Orphomed Inc Dímero de buprenorfina e o seu uso no tratamento de transtornos gastrointestinais
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
CA2965895C (en) * 2014-11-07 2019-08-06 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
ES2836805T3 (es) * 2015-08-03 2021-06-28 Tolmar International Ltd Sistema de administración de polímeros líquidos para la administración extendida de fármacos
FI3377041T3 (fi) 2015-11-16 2023-11-30 Medincell S A Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen
LT3512518T (lt) 2016-09-13 2023-02-10 Alar Pharmaceuticals Inc. Sulėtinto atpalaidavimo buprenorfino vaisto formos
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CA3089114A1 (en) 2018-01-22 2019-07-25 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
AU2019266795B2 (en) 2018-05-11 2023-02-09 Alar Pharmaceuticals Inc. Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
US20210393618A1 (en) 2018-10-11 2021-12-23 Indivior Uk Limited Buprenorphine to treat respiratory depression
US12403291B2 (en) * 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
DK1125577T3 (da) 1994-04-08 2006-06-19 Qlt Usa Inc Væskeformige medikamentindföringspræparater
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
CN1713890A (zh) * 2002-11-06 2005-12-28 阿尔萨公司 控释储库制剂
EP1622540A4 (en) * 2003-03-11 2009-12-30 Qlt Usa Inc PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
DK1824460T3 (en) * 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
PL3660073T3 (pl) 2007-02-15 2023-12-27 Tolmar International Limited Poli(laktyd-ko-glikolid) o niskim nagłym uwalnianiu
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
JP5986072B2 (ja) 2016-09-06
SG186200A1 (en) 2013-01-30
MY171625A (en) 2019-10-21
GB2481018B (en) 2015-03-18
CA2801676A1 (en) 2011-12-15
RU2607498C2 (ru) 2017-01-10
MX2012014335A (es) 2013-03-05
GB201009549D0 (en) 2010-07-21
HRP20180118T1 (hr) 2018-03-09
DK3360538T3 (da) 2023-03-06
EP3360538B1 (en) 2023-02-15
GB201413064D0 (en) 2014-09-03
IL254417A0 (en) 2017-11-30
ES2939612T3 (es) 2023-04-25
CN103079544B (zh) 2017-06-09
AU2011263478A1 (en) 2013-01-10
CL2012003462A1 (es) 2013-04-01
CN103079544A (zh) 2013-05-01
NO2579874T3 (enExample) 2018-06-09
EP4218720A1 (en) 2023-08-02
SI2579874T1 (en) 2018-03-30
RS56820B1 (sr) 2018-04-30
US20130210853A1 (en) 2013-08-15
CO6670529A2 (es) 2013-05-15
ZA201209233B (en) 2014-04-30
MX339209B (es) 2016-04-15
FI3360538T3 (fi) 2023-03-22
ES2656938T3 (es) 2018-03-01
GB2513267B (en) 2015-03-18
PL2579874T3 (pl) 2018-05-30
CA2801676C (en) 2018-08-07
WO2011154724A2 (en) 2011-12-15
JP2016155865A (ja) 2016-09-01
HUE038275T2 (hu) 2018-10-29
SMT201800038T1 (it) 2018-03-08
JP6251774B2 (ja) 2017-12-20
EP3360538A1 (en) 2018-08-15
WO2011154724A9 (en) 2012-08-16
DK2579874T3 (da) 2018-01-29
IL223488A (en) 2017-10-31
AU2011263478B2 (en) 2015-01-22
KR101865689B1 (ko) 2018-06-08
WO2011154724A3 (en) 2012-07-12
EP2579874A2 (en) 2013-04-17
GB2513267A (en) 2014-10-22
RU2012157244A (ru) 2014-07-20
GB2481018A (en) 2011-12-14
JP2013533230A (ja) 2013-08-22
LT2579874T (lt) 2018-02-12
BR112012031290A2 (pt) 2016-11-01
EP2579874B1 (en) 2018-01-10
CY1120761T1 (el) 2019-12-11
US8921387B2 (en) 2014-12-30
KR20130135026A (ko) 2013-12-10
NZ604026A (en) 2015-01-30

Similar Documents

Publication Publication Date Title
IL254417A0 (en) A flowable, injectable preparation containing buprenorphine
GB201002983D0 (en) Nutritinal composition
GB201006200D0 (en) Composition
GB201021186D0 (en) Composition
LT2579875T (lt) Kompozicijos, apimančios buprenorfiną
ZA201207055B (en) Composite additive materials
GB201006178D0 (en) Composition
EP2570141A4 (en) DERIVATIVE FILLING COMPOSITION
GB201021269D0 (en) Composition
GB201016970D0 (en) Composition
IL206739A0 (en) Injectable pharmaceutical composition
PL2625258T3 (pl) Kompozycja do czyszczenia z polimerów
GB201019988D0 (en) Composition
GB201007531D0 (en) Composition
GB201006214D0 (en) Composition
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
GB201014967D0 (en) Composition
GB201010657D0 (en) Composition
PL2534235T3 (pl) Kompozycja
GB201018130D0 (en) Composition
GB201006012D0 (en) Composition
GB201003768D0 (en) Composition
GB201005378D0 (en) Composition
GB201005377D0 (en) Composition